Serum IgE in Primary Glomerular Diseases

Nephron ◽  
1984 ◽  
Vol 36 (1) ◽  
pp. 5-9 ◽  
Author(s):  
G. Lagrue ◽  
J. Laurent ◽  
G. Hirbec ◽  
J.C. Ansquer ◽  
C. Noirot ◽  
...  
Keyword(s):  
Glomerular Diseases ◽  
Serum Ige ◽  
Primary Glomerular Diseases

Serum IgE in Primary Glomerular Diseases and Its Clinical Significance

Nephron ◽  
1988 ◽  
Vol 49 (1) ◽  
pp. 24-28 ◽  
Author(s):  
Kuo-hsiung Shu ◽  
Jong-da Lian ◽  
Yun-fu Yang ◽  
Yuan-san Lu ◽  
Jye-yang Wang
Keyword(s):  
Clinical Significance ◽  
Glomerular Diseases ◽  
Serum Ige ◽  
Primary Glomerular Diseases

Progression of Renal Failure in Chronic Primary Glomerular Diseases

Nephron ◽  
1994 ◽  
Vol 68 (1) ◽  
pp. 32-37 ◽  
Author(s):  
Ana Gonzalo ◽  
Araceli Gallego ◽  
Maite Rivera ◽  
Nieves Gallego ◽  
Joaquín Ortuño
Keyword(s):  
Renal Failure ◽  
Glomerular Diseases ◽  
Progression Of Renal Failure ◽  
Primary Glomerular Diseases

P0453BIOSIMILAR RITUXIMAB AND BRAND RITUXIMAB: RELAPSES AND PROTEINURIA IN THE GLOMERULAR PRYMARY DISEASES

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Roxana Bury ◽  
Irene Agraz ◽  
Maria Jose Soler Romeo ◽  
Clara Garcia Carro ◽  
Eugenia Espinel ◽  
...  
Keyword(s):  
Lymphocyte Count ◽  
Leucocyte Count ◽  
Statistical Significance ◽  
Laboratory Data ◽  
Small Sample ◽  
Response To Treatment ◽  
Glomerular Diseases ◽  
Non Hodgkin Lymphoma ◽  
Before And After ◽  
Primary Glomerular Diseases

Abstract Background and Aims Biosimilar drugs need to prove similar effectiveness to the brand name drug, in order to have their authorization from regulatory agencies. Rituximab initially developed as a treatment for non-Hodgkin lymphoma, is used as a therapeutic alternative to several autoimmune diseases, including primary glomerular diseases. The objective of this study is to observe if there were differences in terms of effects measured in proteinuria and relapse episodes between rituximab brand versus biosimilar in primary glomerular diseases Method This is a retrospective descriptive study that included patients receiving rituximab brand or biosimilar for the first time between March 2018 to March 2019, collecting information from the reported medical records with primary glomerulopathy were included. The collected laboratory data included creatinine, proteinuria, leukocyte and lymphocyte count before (0-60 days before) and after (0-60 days after) administration of rituximab. Results A total of 19 patients with primary glomerulopathy were included. Six patients (59-years-old (26-74); 50% female) with baseline 6.52±2.00x10^9/L leucocyte count, 2.28±1.10x10^9/L lymphocyte count, 1.63±1.04 mg/dL creatinine and 6.84±3.36g/24h proteinuria, were treated with biosimilar-rituximab. Thirteen patients (58-years-old (25-81); 30% female) with baseline 9.80±4.62x10^9/L leucocyte count, 1.92±1.13 x10^9/L lymphocyte count, 1.61±0.85 mg/dL creatinine and 5.81±4.55 g/24h proteinuria, were treated with brand-rituximab. After the rituximab administration, these values were 6.13±1.94x10^9/L leucocyte count, 1.30±0.59x10^9/L lymphocyte count, 1.16±1.19 mg/dL creatinine, 3.29±0.58g/24h and proteinuria for the biosimilar group; and 8.77±3.78x10^9/L leucocyte count, 1.67±1.13x10^9/L lymphocyte count, 1.56±1.19 mg/dL creatinine and 3.36±2.20g/24h proteinuria for the brand group. After rituximab administration CD19+ lymphocytes become negative in both groups (5/5 for the biosimilar group; 6/6 for the brand group). There were 2 total remissions, 1 partial remission and 3 without response with the biosimilar and 1 total remission, 5 partial remissions and 7 without response with the rituximab brand. Biosimilar was well tolerated in 6/6 patients and Rituximab brand infection did not develop was well tolerated in 11/13 patients and 4/13 patients showed an episode of infection. No statistically significant results were observed for the response to treatment between both groups. Conclusion The biosimilar shows a similar profile in terms of proteinuria and remissions against rituximab mark in the reported follow-up period, however our study is limited since it has a small sample, so a larger study is necessary to demonstrate these results with statistical significance

Anti-HCV Antibodies in Primary Glomerular Diseases in India

Nephron ◽  
2000 ◽  
Vol 84 (3) ◽  
pp. 290-290
Author(s):  
S.K. Agarwal ◽  
S.C. Dash ◽  
M. Irshad ◽  
A. Dinda
Keyword(s):  
Glomerular Diseases ◽  
Primary Glomerular Diseases

Primary glomerular diseases in the elderly Glomerulonephritis in the elderly

1996 ◽  
Vol 6 (2) ◽  
pp. 105-112 ◽  
Author(s):  
Claudio Ponticelli ◽  
Patrizia Passerini ◽  
Donata Cresseri
Keyword(s):  
The Elderly ◽  
Glomerular Diseases ◽  
Primary Glomerular Diseases

Increasing prevalence of membranous nephropathy in patients with primary glomerular diseases: A cross-sectional study in China

Nephrology ◽  
2017 ◽  
Vol 22 (2) ◽  
pp. 168-173 ◽  
Author(s):  
Lijun Tang ◽  
Jing Yao ◽  
Xianglei Kong ◽  
Qing Sun ◽  
Zunsong Wang ◽  
...  
Keyword(s):  
Membranous Nephropathy ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Glomerular Diseases ◽  
Primary Glomerular Diseases

scholarly journals Most common histopathological patterns of the Minas Gerais Association of the Centers of Nephrology

2019 ◽  
Vol 65 (3) ◽  
pp. 441-445 ◽  
Author(s):  
Soraia Goretti Rocha Machado ◽  
Thiago Quadros ◽  
Yoshimi Watanabe ◽  
Cecília F Aquino ◽  
Alba Otoni ◽  
...  
Keyword(s):  
Kidney Biopsy ◽  
Kidney Diseases ◽  
Minas Gerais ◽  
Regions Of Interest ◽  
Ultrasound Guided ◽  
Glomerular Diseases ◽  
Disease Registries ◽  
Primary Glomerular Diseases ◽  
Public Policy Decisions ◽  
Secondary Diseases

SUMMARY INTRODUCTION: We analyzed the distribution and frequency of glomerular diseases in patients biopsied between 1992 and 2016 in centers that make up the AMICEN (Minas Gerais Association of Nephrology Centers). METHODS: We analyzed the biopsy reports of patients from 9 AMICEN nephrology centers. We took note of their age, gender, ultrasound use, post-biopsy resting time, whether the kidney was native or a graft, number of glomeruli and indication for the biopsy. The kidney biopsy findings were broken down into four categories: glomerular and non-glomerular diseases, normal kidneys and insufficient material for analysis. Those patients diagnosed with glomerular diseases were further divided into having primary or secondary glomerular diseases. RESULTS: We obtained 582 biopsy reports. The median age was 38 years (1 to 85). The number of glomeruli varied between 0 and 70 (median = 13.0). In total, 97.8% of the biopsies were ultrasound guided. The main indication was nephrotic syndrome (36.9%), followed by hematuria-proteinuria association (16.2%). Primary glomerular diseases proved to be the most frequent (75.3%), followed by secondary diseases (24.7%). Among the primary glomerular diseases, FSGS was found at a higher frequency (28.8%), while among the secondary diseases, SLE was the most prevalent (42.4%). Regarding prevalence findings, those for both primary and secondary diseases were similar to those found in the large Brazilian registries published thus far. CONCLUSION: Glomerular disease registries are an important tool to identify the prevalence of such disease in regions of interest and can serve as an instrument to guide public policy decisions concerning the prevention of terminal kidney diseases.

scholarly journals Establishment of a novel nomogram for the clinically diagnostic prediction of minimal change disease, −a common cause of nephrotic syndrome

2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Gaofei Yan ◽  
Guanzhi Liu ◽  
Xuefei Tian ◽  
Lifang Tian ◽  
Hao Wang ◽  
...  
Keyword(s):  
Nephrotic Syndrome ◽  
Renal Biopsy ◽  
Minimal Change Disease ◽  
Clinical Manifestations ◽  
Minimal Change ◽  
Adult Patients ◽  
Lasso Regression ◽  
Glomerular Diseases ◽  
Laboratory Test Results ◽  
Primary Glomerular Diseases

Abstract Background Minimal change disease (MCD) is one of the major causes of nephrotic syndrome (NS). A confirmed MCD diagnosis mainly depends on renal biopsy at present, which is an invasive procedure with many potential risks. The overall incidence of complications caused by renal biopsy procedures has been reported as approximately 11 and 6.6% outside and within China, respectively. Unfortunately, there is currently no noninvasive procedure or practical classification method for distinguishing MCD from other primary glomerular diseases available. Method A total of 1009 adult patients who underwent renal biopsy between January 2017 and November 2019 were enrolled in this study. Twenty-five parameters extracted from patient demographics, clinical manifestations, and laboratory test results were statistically analysed. LASSO regression analysis was further performed on these parameters. The parameters with the highest area under the curve (AUC) were selected and used to establish a logistic diagnostic prediction model. Results Of the 25 parameters, 14 parameters were significantly different (P < 0.05). MCD patients were mostly younger (36 (22, 55) vs. 41 (28.75, 53)) and male (59% vs. 52%) and had lower levels of diastolic blood pressure (DBP) (79 (71, 85.5) vs. 80 (74, 89)) and IgG (5.42 (3.17, 6.36) vs. 9.38 (6.79, 12.02)) and higher levels of IgM (1.44 (0.96, 1.88) vs. 1.03 (0.71, 1.45)) and IgE (160 (46.7, 982) vs. 47.3 (19, 126)) than those in the non-MCD group. Using the LASSO model, we established a classifier for adults based on four parameters: DBP and the serum levels of IgG, IgM, IgE. We were able to clinically classify adult patients with NS into MCD and non-MCD using this model. The validation accuracy of the logistic regression model was 0.88. A nomogram based on these four classifiers was developed for clinical use that could predict the probability of MCD in adult patients with NS. Conclusions A LASSO model can be used to distinguish MCD from other primary glomerular diseases in adult patients with NS. Combining the model and the nomogram potentially provides a novel and valuable approach for nephrologists to diagnose MCD, avoiding the complications caused by renal biopsy.

Sign in / Sign up

Export Citation Format

Share Document